Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $15.6700 (-1.63%) ($15.5700 - $16.4300) on Wed. Apr. 19, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2% (three month average) | RSI | 17 | Latest Price | $15.6700(-1.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.7% a day on average for past five trading days. | Weekly Trend | ADMS declines -3.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) ARKG(18%) XOP(18%) ARKK(17%) | Factors Impacting ADMS price | ADMS will decline at least -1% in a week (0% probabilities). VIXM(-11%) UUP(-10%) UNG(-8%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1% (StdDev 2%) | Hourly BBV | 0 () | Intraday Trend | -2.3% | | | |
|
1 - 5 Day Possible Target | $9.21(-41.23%) | Resistance Level | $16.78 | 5 Day Moving Average | $15.98(-1.94%) | 10 Day Moving Average | $16.28(-3.75%) | 20 Day Moving Average | $16.78(-6.62%) | To recent high | -15.3% | To recent low | 5.4% | Market Cap | $443m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |